{"ticker": {"uuid": "5eec2eb7-c752-428d-aacf-90e20518de10", "symbol": "IMVT", "name": "Immunovant\u00a0Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Form 4 Immunovant Inc For: 10 July By Investing.com", "summary": "This article from Investing.com announces the filing of a Form 4 for Immunovant Inc. on July 10th. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the beneficial ownership of a company's securities by ", "url": "https://ng.investing.com/news/stock-market-news/form-4-immunovantinc-for-10-july-93CH-2595505", "source_name": "Investing.com Nigeria", "published_at": "2026-07-11T17:10:10", "published_display": "11 Jul 2026 17:10", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant CTO Jay Stout sells $137,924 in IMVT stock", "summary": "Immunovant's CTO, Jay Stout, sold 3,487 shares of IMVT stock totaling $137,924. These were \"sell to cover\" transactions to meet tax obligations from vested restricted stock units, not discretionary sales. The stock has seen a significant 135% gain over the past year, though Inves", "url": "https://www.investing.com/news/insider-trading-news/immunovant-cto-jay-stout-sells-137924-in-imvt-stock-93CH-4786808", "source_name": "Investing.com", "published_at": "2026-07-11T05:09:18", "published_display": "11 Jul 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant chief legal officer Van Tuyl sells $47,702 in stock", "summary": "Immunovant's Chief Legal Officer, Christopher Van Tuyl, recently sold 1,206 shares of company stock for a total of $47,702 to cover tax withholding obligations related to restricted stock units. Following these transactions, Van Tuyl still holds 179,391 shares. The stock has seen", "url": "https://www.investing.com/news/insider-trading-news/immunovant-chief-legal-officer-van-tuyl-sells-47702-in-stock-93CH-4786834", "source_name": "Investing.com", "published_at": "2026-07-10T21:09:18", "published_display": "10 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant COO Melanie Gloria sells $80,531 in shares", "summary": "Immunovant COO Melanie Gloria sold $80,531 worth of company common stock on July 8, 2026, to cover tax withholding obligations related to the vesting of restricted stock units. Following these transactions, Ms. Gloria directly holds 222,357 shares. The sale occurred while Immunov", "url": "https://www.investing.com/news/insider-trading-news/immunovant-coo-melanie-gloria-sells-80531-in-shares-93CH-4786803", "source_name": "Investing.com", "published_at": "2026-07-10T20:09:18", "published_display": "10 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant (IMVT) COO offloads 2,036 shares to cover RSU tax withholding", "summary": "Immunovant, Inc.'s Chief Operating Officer, Gloria Melanie, sold 2,036 shares of common stock on July 8, 2026. These sales were not discretionary but were mandated \"sell to cover\" transactions to meet tax withholding obligations from the vesting of restricted stock units (RSUs). ", "url": "https://www.stocktitan.net/sec-filings/IMVT/form-4-immunovant-inc-insider-trading-activity-0a21246654a0.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:09:18", "published_display": "10 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant (IMVT) CTO offloads 3,487 shares in mandated RSU tax-withholding sales", "summary": "Immunovant's Chief Technology Officer, Jay S. Stout, sold 3,487 shares of IMVT common stock on July 8, 2026. These sales were non-discretionary \"sell to cover\" transactions to meet tax withholding obligations due to the vesting of restricted stock units (RSUs). The sales occurred", "url": "https://www.stocktitan.net/sec-filings/IMVT/form-4-immunovant-inc-insider-trading-activity-4dc2a4540837.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:09:18", "published_display": "10 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant (IMVT) legal chief sells 1,206 shares in tax \u201csell to cover\u201d", "summary": "Christopher Van Tuyl, Immunovant's Chief Legal Officer, sold 1,206 shares of common stock on July 8, 2026, in a mandatory \"sell to cover\" transaction. This sale, totaling approximately $47,702, was executed to satisfy tax withholding obligations following the vesting of previousl", "url": "https://www.stocktitan.net/sec-filings/IMVT/form-4-immunovant-inc-insider-trading-activity-a6b52dfbbd06.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:09:18", "published_display": "10 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $53", "summary": "LifeSci Capital has reiterated its Buy rating for Immunovant (IMVT.US) and increased its price target for the stock to $53. This indicates a continued positive outlook from the firm regarding Immunovant's financial prospects and market valuation.", "url": "https://www.moomoo.com/news/post/72720093/lifesci-capital-maintains-immunovant-imvtus-with-buy-rating-raises-target", "source_name": "Moomoo", "published_at": "2026-07-10T05:39:41", "published_display": "10 Jul 2026 05:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant Inc explores long term growth paths as autoimmune pipeline advances", "summary": "Immunovant Inc is focusing on developing therapies for autoimmune diseases and expanding its pipeline. The company's long-term growth is dependent on successful clinical trials", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/immunovant-inc-explores-long-term-growth-paths-as-autoimmune-pipeline/69731709", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-09T12:10:44", "published_display": "09 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant stock hits 52-week high at 39.28 USD", "summary": "Immunovant Inc. (IMVT) stock reached a new 52-week high of $39.28, marking a 130.79% increase over the past year. This surge is fueled by positive results from its Phase 2 rheumatoid arthritis study of IMVT-1402, with analysts from H.C. Wainwright, BofA Securities, and Stifel rai", "url": "https://www.investing.com/news/company-news/immunovant-stock-hits-52week-high-at-3928-usd-93CH-4779660", "source_name": "Investing.com", "published_at": "2026-07-08T04:40:23", "published_display": "08 Jul 2026 04:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding Momentum Shifts in (IMVT)", "summary": "This article analyzes Immunovant Inc. (IMVT) using AI-generated signals, indicating a strong overweight bias across all time horizons. It provides detailed trading strategies for different risk profiles, including position, momentum breakout, and risk hedging, along with multi-ti", "url": "https://news.stocktradersdaily.com/news_release/9/Understanding_Momentum_Shifts_in_IMVT_070826050202_1783501322.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-08T04:40:13", "published_display": "08 Jul 2026 04:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant stock hits 52-week high at 39.28 USD By Investing.com", "summary": "Immunovant Inc. (IMVT) stock reached a new 52-week high of $39.28, marking a 130.79% increase over the past year and achieving a market capitalization of $8.01 billion. This surge is supported by positive analyst ratings and promising results from its Phase 2 rheumatoid arthritis", "url": "https://za.investing.com/news/stock-market-news/immunovant-stock-hits-52week-high-at-3928-usd-93CH-4358888", "source_name": "Investing.com South Africa", "published_at": "2026-07-07T23:40:13", "published_display": "07 Jul 2026 23:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant Inc outlines its autoimmune drug pipeline as investors watch clinical milestones", "summary": "Immunovant Inc is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases using targeted antibody inhibition. The company's pipeline includes treatments for neuromuscular disorders and dermatologic autoimmune diseases, with development h", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/immunovant-inc-outlines-its-autoimmune-drug-pipeline-as-investors-watch/69714194", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T14:13:52", "published_display": "07 Jul 2026 14:13", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant (IMVT) CEO settles CVARs with small tax-related share sale", "summary": "Immunovant, Inc. CEO Eric Venker reported the settlement of 92,188 vested capped value appreciation rights (CVARs) into common stock on July 1, 2026, after meeting service, performance, and knock-in conditions. Concurrently, he disposed of 86,629 shares to the issuer and sold 3,0", "url": "https://www.stocktitan.net/sec-filings/IMVT/form-4-immunovant-inc-insider-trading-activity-975da4c0365c.html", "source_name": "Stock Titan", "published_at": "2026-07-07T04:40:23", "published_display": "07 Jul 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant CEO Eric Venker sells $118,980 of IMVT stock By Investing.com", "summary": "Immunovant CEO Eric Venker recently sold 3,092 shares of Immunovant (NASDAQ:IMVT) common stock for approximately $118,980. This \"sell to cover\" transaction was executed to fulfill tax withholding obligations tied to the vesting of Capped Value Appreciation Rights (CVARs). The sal", "url": "https://ca.investing.com/news/stock-market-news/immunovant-ceo-eric-venker-sells-118980-of-imvt-stock-93CH-4721754", "source_name": "Investing.com Canada", "published_at": "2026-07-07T04:09:56", "published_display": "07 Jul 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant CEO Eric Venker sells $118,980 of IMVT stock", "summary": "Immunovant CEO Eric Venker sold 3,092 shares of company common stock worth $118,980 to cover tax withholding obligations related to the vesting of Capped Value Appreciation Rights (CVARs). The transaction occurred on July 2, 2026, with the shares sold at $38.48 each. Following th", "url": "https://www.investing.com/news/insider-trading-news/immunovant-ceo-eric-venker-sells-118980-of-imvt-stock-93CH-4777626", "source_name": "Investing.com", "published_at": "2026-07-06T22:13:52", "published_display": "06 Jul 2026 22:13", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Immunovant Inc For: 6 July By Investing.com", "summary": "This article announces the filing of a Form 4 for Immunovant Inc. on July 6. Form 4 filings typically report changes in beneficial ownership of a company's securities by insiders. The article provides the title of the filing but no further details about its content.", "url": "https://ca.investing.com/news/stock-market-news/form-4-immunovantinc-for-6-july-93CH-4721762", "source_name": "Investing.com Canada", "published_at": "2026-07-06T21:09:55", "published_display": "06 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMVT - Immunovant Inc Revenue Breakdown", "summary": "This article provides a detailed financial overview of Immunovant Inc. (IMVT), covering key metrics such as market cap, income, sales, stock performance, and analyst recommendations. It highlights the company's valuation ratios, insider and institutional ownership, and profitabil", "url": "https://finviz.com/stock?t=IMVT&ty=rv", "source_name": "Finviz", "published_at": "2026-07-04T11:09:45", "published_display": "04 Jul 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chief Technology Officer Of Immunovant Sold 53% Of Their Shares", "summary": "Immunovant Inc.'s Chief Technology Officer, Jay Stout, recently sold US$1.5 million worth of stock, representing 53% of his holding. While insider selling at the current price isn't as concerning as selling at a lower price, there has been no insider buying in the last year. Insi", "url": "https://www.sahmcapital.com/news/content/chief-technology-officer-of-immunovant-sold-53-of-their-shares-2026-07-02", "source_name": "Sahm", "published_at": "2026-07-04T03:39:54", "published_display": "04 Jul 2026 03:39", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMVT - Immunovant Inc Options", "summary": "This page provides a detailed financial overview of Immunovant Inc (IMVT), including its latest stock performance, market capitalization, income, sales, and various financial ratios. It also lists key statistics such as EPS, insider and institutional ownership, profitability metr", "url": "https://finviz.com/stock?t=IMVT&ty=oc&ov=chain_strike&s=22", "source_name": "Finviz", "published_at": "2026-07-03T02:39:15", "published_display": "03 Jul 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citi Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $61", "summary": "Citi has reiterated its Buy rating for Immunovant (IMVT.US) and increased the target price to $61. This indicates a continued positive outlook from Citi on the company's stock performance.", "url": "https://www.moomoo.com/news/post/72258807/citi-maintains-immunovant-imvtus-with-buy-rating-raises-target-price", "source_name": "Moomoo", "published_at": "2026-06-30T14:39:15", "published_display": "30 Jun 2026 14:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant Insider Sold Shares Worth $1,532,309, According to a Recent SEC Filing", "summary": "An insider at Immunovant recently sold shares valued at $1,532,309, as disclosed in a recent SEC filing. This transaction could be of interest to investors tracking insider activity within the company. Further details would typically be available in the full SEC document.", "url": "https://www.moomoo.com/news/post/72169892/immunovant-insider-sold-shares-worth-1532309-according-to-a-recent?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-29T08:13:24", "published_display": "29 Jun 2026 08:13", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant CTO Jay Stout sells $1.53m in company stock", "summary": "Immunovant CTO Jay Stout sold 40,000 shares of the company\u2019s common stock for over $1.53 million on June 26, 2026. This sale occurred while Immunovant shares were trading near their 52-week high, with InvestingPro analysis suggesting the stock is overvalued. Despite this insider ", "url": "https://www.investing.com/news/insider-trading-news/immunovant-cto-jay-stout-sells-153m-in-company-stock-93CH-4763870", "source_name": "Investing.com", "published_at": "2026-06-27T13:40:21", "published_display": "27 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant (IMVT) CTO Jay S. Stout sells 40,000 shares in open-market trades", "summary": "Immunovant, Inc. CTO Jay S. Stout reported selling a total of 40,000 shares of the company's common stock in two open-market transactions on June 26, 2026. The shares were sold at weighted average prices of $38.18 and $38.94 per share, totaling approximately $1.53 million. Follow", "url": "https://www.stocktitan.net/sec-filings/IMVT/form-4-immunovant-inc-insider-trading-activity-6fe49a2c1b17.html", "source_name": "Stock Titan", "published_at": "2026-06-27T11:39:44", "published_display": "27 Jun 2026 11:39", "sentiment": "negative", "sentiment_pct": 14, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Melanie Gloria Sells 17,714 Shares of Immunovant I", "summary": "Melanie Gloria, Chief Operating Officer at a subsidiary of Immunovant Inc (IMVT), sold 17,714 shares of the company on June 26, 2026. Following this transaction, Gloria now owns 224,393 shares. Immunovant Inc is a clinical-stage biopharmaceutical company, and this sale marks part", "url": "https://www.gurufocus.com/news/8935069/insider-sell-melanie-gloria-sells-17714-shares-of-immunovant-inc-imvt", "source_name": "GuruFocus", "published_at": "2026-06-27T02:39:44", "published_display": "27 Jun 2026 02:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Immunovant, Inc. \u2013 NASDAQ:IMVT", "summary": "This article from TradingView focuses on the \"Price to book forward\" financial metric for Immunovant, Inc. (NASDAQ: IMVT). It is primarily a data page, displaying the period, value, and change for this specific financial indicator related to the biotechnology company. The content", "url": "https://www.tradingview.com/symbols/NASDAQ-IMVT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T01:13:24", "published_display": "27 Jun 2026 01:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant CFO Tiago Girao sells $384,600 in company stock", "summary": "Immunovant (NASDAQ:IMVT) CFO Tiago Girao sold 10,000 shares of company stock for approximately $384,600 after exercising stock options for the same number of shares. The sale occurred while Immunovant shares were trading near their 52-week high, having delivered a 137% return ove", "url": "https://www.investing.com/news/insider-trading-news/immunovant-cfo-tiago-girao-sells-384600-in-company-stock-93CH-4763861", "source_name": "Investing.com", "published_at": "2026-06-27T00:39:44", "published_display": "27 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant chief legal officer sells $682,886 in stock", "summary": "Christopher Van Tuyl, Chief Legal Officer at Immunovant, Inc. (NASDAQ:IMVT), sold 17,824 shares of company stock for $682,886 on June 26, 2026, after exercising stock options. The sales occurred while the stock was near its 52-week high, following a significant 137% gain over the", "url": "https://www.investing.com/news/insider-trading-news/immunovant-chief-legal-officer-sells-682886-in-stock-93CH-4763862", "source_name": "Investing.com", "published_at": "2026-06-27T00:39:44", "published_display": "27 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant (IMVT) Chief Legal Officer sells 17,824 shares after option exercise", "summary": "Immunovant, Inc.'s Chief Legal Officer, Christopher Van Tuyl, exercised options for 17,824 shares at $15.20 each and subsequently sold all these shares in open-market transactions for approximately $38.19 to $38.96 per share. Following these transactions, Van Tuyl directly holds ", "url": "https://www.stocktitan.net/sec-filings/IMVT/form-4-immunovant-inc-insider-trading-activity-14d28f1a79c5.html", "source_name": "Stock Titan", "published_at": "2026-06-27T00:10:21", "published_display": "27 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant (IMVT) COO sells 17,714 shares, keeps 224,393 stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPSE5lNFFXSF91b21JdmtiYVRoaGJUTEpPSGFpTmEteFcxbWZfbFAxMGhfRVpLakRrUi1MOEtzU3ZrV1RNby1ObWcwS182d1hIb1ZxMFB1clVkZXFzM1FMd0hOS3FaYy1qVmRZUUdlOUJrOHJoN2xfV3JqSTFNQ3JhVWY3MmJ2NXRMb1JCMlpQVGtINkY1WlhzN3ZQeUR5WHdlV3hWemxHcGk2TFIx?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Immunovant, Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQU0dEY3NEMzR1Tm8yWEtSWkcydG9QS2J1cllvRk5LTHMxa0cxdVl6RWkybGJUZlk5REZXb1NsbXlFaVVpWnNaMHFuVHVfX1ZzaGlRcDRqd2ktdExvMlhCdEdoUVJPYkdwa0FRS3FGNGFWSlVmSmxmVHpVNE1oZDRmRTlrN2stLXNNQVRyVFlPX19YNmo4dUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMVT (NASDAQ) Form 144 lists multiple vested restricted stock blocks, 40,000 header", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQb0lzbTc1YzJwem53SnpvME5zMC1BTmFBOGN2aFdSLWRDM3dsN0NKWXBtUWdmMHVJdjlFOTREVVFEcGJVSmRCSDhOTWN4TUJhMVdvM1pzR1RCMjBZOGNSYWQ4cmJKenhZOW5RZWtLd0xQcEV6V2xLNlFGZzNGQllMS0Y2OFVoU205ek5jQjV5MEV2ZkdYT0E?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant (IMVT) director sells 1,500 shares after option exercise", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOclR1R1ZUUkFFY3lVV29sN0ppOTRvZ0F4elRVQ3BRcTliWm1XdGEzMkpTaE5GUTBoM2FmVHM1V1dBVVZBaS1MZWV3Sl9PbjFiS3BZMkZEa3BKMXJFaDlUTnJwdHZoQmZzYVY2aE1EU3JLa1A1Z3F5ZnFxeHNpLWN6cTR2ZUtqVXltdF94UzFBNWxNcnpWSW9wZm9QSnJSV0I4cWt3QWQzSE15dkJ3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant (IMVT) Stock Could Be 14.1% Undervalued After Loss And Trial Updates", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-20T07:00:00+00:00", "published_display": "20 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/immunovant-imvt-3-6-since-153004858.html", "source_name": "Zacks", "published_at": "2026-06-19T15:30:04+00:00", "published_display": "19 Jun 2026 15:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant (IMVT) Is Up 7.5% After Batoclimab Shows Phase IIb CIDP Benefit - What's Changed", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxQaC1nZHFaNlVsT0ZqU2c2RVpWdk00TUdPeGNScmdpZWtqNEF4TzlOQTlXWnVNbGZVYld4eXhmeUdSRjFuTDVGcXJCSjUydjEyU2tuT3pBTnpXbkN5T3BpUjA4VkpkTzFpcGFRcEt3TEtkc3BEZGRLdTB6dkVhR3hDQnJlSDhiYnF3SXJINGlvcWJtVnhyRGZENll5bklTb08wcnJOcDdBbjZzblV6M1dxUURBUlhrejMta1NiX29hM3VVeHJsSjFKdEZjS1ZTMFFOdzRLQVdmYS1QUXVP0gHiAUFVX3lxTE5USkVRMTVjVmlER0VXVUlFQTFkakNlYUxDWVk2ZDRmTWNwSXo2MVUyaHRYWVdlYUhCS2ZQWU9iWmhnbjVZWGlhUEJnVlE0cFVzVWlpUGdZYjVTcjc1b001dl9weXhFcmotN1J0d2pxcS0xdFRrX2U2anFJS2IyM2dzYXBSN0hlZzd3NHhRQ3lKT2RyNEdIZ0hZaXdwRHFNU1U1clBYUmhMSWtVdWMyaW9XeGVlR0JqOWdGY0I5TTZnVjZRNzRDRjRCN1htUF9aRU5BSlpLTkJMSUQ5b0NpWUFSRnc?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant (IMVT) director trades 1,500 shares under 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNZ191X3NNU09xaTJ6czRnX1pGdVRxOGNxb3Y5eHA3bG1NM1pCWWQ4cEJtaDlKOHUwX1I3aTk3UzRTbG13NllPcVdOLUpJUTlJVXFSOHA4NTdiUTFvdGc2V2Mza05Vc1lnMHh0RzdmbzZOeU9fUnFvVmNXeHdTWjZpdU9TLUFuaG9jUjNSMG5QR2p1Rm5VaENsNy1DNll1WDNMNE9YV1R1ekNoYjVF?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant Stock Gains 12.4% in a Month: What's Driving It?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQVWJ6Mm9ZNTNZVjRiT0V3d2ZOS29RYVgwcElkQlg5ZDlXZ3FGQmplRVViVWxFekZOT3RGTUVjMHZVSnhFTDNGNTd1d19uLVNkdHJ6N0FoVjlaekxncWZTQmI0R0tFSlJTY0g0czVRSTJJTW9kSGdzVkdueGNvYjlWZWRMUmRZajhHNW9Ta1pSeHd2QTJpN293?oc=5", "source_name": "Market source", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Immunovant (IMVT) Valuation After Strong IMVT 1402 Phase 2 Rheumatoid Arthritis Trial Commentary", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/assessing-immunovant-imvt-valuation-strong-081221741.html", "source_name": "Simply Wall St.", "published_at": "2026-06-05T08:12:21+00:00", "published_display": "05 Jun 2026 08:12", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNbWFtRHZpVGZiSFc4OUN2amltaUNmNU5uMjVYVTEwYzhvbFB4T1N2M0VBaWFtREtQY1F0S0R3OXNqdWxCY21EQUpkOFprbjRwZzhxR0htR2o0YUFLUFlDd1BrdmYtVnNuZUVkWGVsSmFFVU1RUy1FTXVlbmhEQUctWjg3RktOd0ZKd0pWQW4ydTZsT0NJQ2E2MjRXLW0?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant(IMVT.US) Director Sells US$7.44 Million in Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPNkZRbmN3SzB2QlpsWGphNkZMYTFVZG85S093OVNUX0FMZTZYUGxIS25RLW1zS2ZUbDZnWDlMVHJENzBwbmlxZ3pnQkRZWlJ1NFA2TXN2c2hBaGczUE1vNnlYM0U3YjAyYmlxbDBzOE1zR1l4MFlaQnpYVjJfQW5xbkdBdUVrVVFGbVo4dFBzUktxNVpNc1BWdFdHcU40ODlvamc?oc=5", "source_name": "Moomoo", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist Lifts PT on Immunovant, Inc. (IMVT) But Maintains a Hold Rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPNFRlQkg1VUVJeEpfU2wyNDFncm9ia1FZNjQwN205SXZRUnp3SEZiTG5ZeU05WThRR29LZHNZV1QyNzlUY1VrRDBpeUNMcUdZdi1jSHZKZms5QmlqR0I1LVU5ZVkxaUE5RUJ5cGV4SFIzNHAwaGFrdzZlQ2JFZXhwVjhkR0FyWTljeFVOWUxtZlY2VS1FNGw3N21Rbw?oc=5", "source_name": "Market source", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan Raises Immunovant Price Target to $47 From $35, Overweight Rating Kept", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/jpmorgan-raises-immunovant-price-target-183230299.html", "source_name": "MT Newswires", "published_at": "2026-05-26T18:32:30+00:00", "published_display": "26 May 2026 18:32", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant (IMVT) Is Up 17.9% After Refocusing On IMVT-1402 Amid Wider Losses - Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOVERrUDdzZTV0c0dIWmZhejcwUmctcm5ZWW9PR2ozeUZOQWxkSWlVdHJEaG1EbXU2TzYzSmJNY01mRGdQbFFtUGVkdTluQTgtczJNaVBXSTB2NGhLVjZKSGxxcTlES3NaMWM0U3U4TVZhbmcxM2Nnb3hwcnBGVzZvZkl2UkcxS3NGYTBaWkZtVEFXZUZpeVR2eUJsMHVEZ2tUMlE?oc=5", "source_name": "Market source", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA raises Immunovant stock price target on higher peak sales outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOeERFa1RkWVRYUWZ4Rk1WNDRNRzBqMzNPcEJHcHNSYXQyVHVyc1NBdTgwdjE1d1FiVUNqOC12bkFnQXd6eXFHZFZuODhKWDdRNkFvcWFNaUU1N2RzWmJqQ0I2S1NhMElSVDYwUUt2UWNrUzRjd29xVEhkMktEZ3djck1IdkZwU18wNUd1SWpKMnYtMkZqbzR1S21VbzFIOUVxY0lYSTFoTkVVakRSbTVXNTVocnk3MHFfQ2pNeHllX3VMVy0wR3FCVDB3?oc=5", "source_name": "Investing.com", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nvidia, Astera Labs, Micron, Intel, United, Hasbro, Toll, Immunovant, Analog Devices, and More Movers", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE5pbFEyblFaaFItUmxyS1BUY2hpNDNrbnFWZ1phREwtUklnUXB2TjJndDhGNGUwSm5Oc1pwZ0RvdHNSblczUGdDZzUzRDQ5UzJiY0k5eXFVRWh5bFliNDBTYm1KTTA?oc=5", "source_name": "Barron's", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMMUNOVANT ($IMVT) Releases Q4 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxNRlU1dUFuMUtfU0QtbVJmMDQtclBCblJ1M2VodXk1ZkZVX0Z3SU5wRWF1Ry1RYWVUcFJNT0VqSVh6SkpBSmhqTmtiN2kyWFhFMDc1TVIwQmx0dTNBTDJ1WTI4cnFIaVhtR0h3REhIaXBVa1lZcGlGMlhPYkFVbFdGUlN3dEVSb184YXhr?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant Shares Rally on Positive Trial Results Despite Earnings Miss (IMVT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQOGNXaExyRjg4ZVlVQlMwVHhiQVNoOHExNkpBejVmQldteUJHcXFYQi1jNjBzMXFnNnpJY0JwTHpHT1UxV04ybGYxWUxuNFNhdE43Qi1NZUdLRFRfYW9JMGl5RjgwTVo0TzM0RmRrU1l3ZjJ6Uzltdm5zQ01BSjNUajRTdFpReWowX1h6LXRZc2x3b2ZLZEt1aHlYaHBSSFkyUFNaNW9WOGpSeE0?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant jumps 30.8% on upbeat IMVT-1402 rheumatoid arthritis update | IMVT Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOZWRMZEhLQVVfME1mYkNOQlVUSmJMank4Q3lLVnVWa1F0Mk5uZTFWQlo2ZmU0eTNLV3hyaWl2dzJOYkV5eE5fakVubzltbEd5SWVFWUdRamYyVjI1NjhPNmhsUXNNNTJicUtKeGdNV0pJd0wxYXpNTUVVN2V1OFFYdFBXM1dFeEZYdEFfRXFPcjRvOU9vZXlfeG1TVlVtVnFMejZEbzVTbG8?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Immunovant: Best-In-Class Ambitions, Still Unproven (NASDAQ:IMVT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQdU5iU2pCem5kM0RYcDlFblUwV1Z5Ql9QLUFmcU9tZkFQMjlMSkp2UVV5amJVQk1xeGFrVlFwNmZVa2pIWEhWTWtZekpFZnFqUXZKWDFvbXpvM1RGWm9Oc0dPSTlTUlI1N2I1aEMycTdZLW1HT0tEOWE3Z2NiaktxM0lucnBaRV9rUFVwQjhVTUF1dUJwMEFPck4zcVE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxQbjV2MjFzZmRGeE1VeU0wNzc4ZlUxMno5QUZlRnRScFQweVBTUDNudGRqMmhYbWFMbGozVXl5TXlBNExOQlNRbk5tb1djLXEwdEV1QTdFdjBxeW8yYVVZclhnX0hIdEhxdTNkZVZEZlNoVHo4VU5PNkl0aUpGZ1Z3alpFUTE?oc=5", "source_name": "Market source", "published_at": "2026-03-15T07:00:00+00:00", "published_display": "15 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxOdjNqcHZzQmJWajN4bXBnOW41U3FlSnY4bldzVFBzdEZSWFpwUEpQX0dJUlRCeG5oeXRlWVY0OTBPdmtsdVdxeExENGhTcDlpVEpLZG84XzA1M1lFaGsyZjhNY3Bxd3p3QUo0d1gzUjNIN1oxeEpLRUQyWFRFVUpiYzZVNE9wZDQ3X1A3S1RKN1hwOFpzREk4TklfYmhDXy16dFNYT2Z2TVZwS2RoQlZOcTI0V1F0OC1FeENqVGQzSEJVeDNZdXpYbXVyZGxyOWNHT2ZDZTNJVFg3WE56S1ZBcDF0WVQ?oc=5", "source_name": "The Motley Fool", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Form 4 Immunovant Inc For: 10 July By Investing.com", "summary": "This article from Investing.com announces the filing of a Form 4 for Immunovant Inc. on July 10th. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the beneficial ownership of a company's securities by ", "url": "https://ng.investing.com/news/stock-market-news/form-4-immunovantinc-for-10-july-93CH-2595505", "source_name": "Investing.com Nigeria", "published_at": "2026-07-11T17:10:10", "published_display": "11 Jul 2026 17:10", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant CTO Jay Stout sells $137,924 in IMVT stock", "summary": "Immunovant's CTO, Jay Stout, sold 3,487 shares of IMVT stock totaling $137,924. These were \"sell to cover\" transactions to meet tax obligations from vested restricted stock units, not discretionary sales. The stock has seen a significant 135% gain over the past year, though Inves", "url": "https://www.investing.com/news/insider-trading-news/immunovant-cto-jay-stout-sells-137924-in-imvt-stock-93CH-4786808", "source_name": "Investing.com", "published_at": "2026-07-11T05:09:18", "published_display": "11 Jul 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant chief legal officer Van Tuyl sells $47,702 in stock", "summary": "Immunovant's Chief Legal Officer, Christopher Van Tuyl, recently sold 1,206 shares of company stock for a total of $47,702 to cover tax withholding obligations related to restricted stock units. Following these transactions, Van Tuyl still holds 179,391 shares. The stock has seen", "url": "https://www.investing.com/news/insider-trading-news/immunovant-chief-legal-officer-van-tuyl-sells-47702-in-stock-93CH-4786834", "source_name": "Investing.com", "published_at": "2026-07-10T21:09:18", "published_display": "10 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant COO Melanie Gloria sells $80,531 in shares", "summary": "Immunovant COO Melanie Gloria sold $80,531 worth of company common stock on July 8, 2026, to cover tax withholding obligations related to the vesting of restricted stock units. Following these transactions, Ms. Gloria directly holds 222,357 shares. The sale occurred while Immunov", "url": "https://www.investing.com/news/insider-trading-news/immunovant-coo-melanie-gloria-sells-80531-in-shares-93CH-4786803", "source_name": "Investing.com", "published_at": "2026-07-10T20:09:18", "published_display": "10 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant (IMVT) COO offloads 2,036 shares to cover RSU tax withholding", "summary": "Immunovant, Inc.'s Chief Operating Officer, Gloria Melanie, sold 2,036 shares of common stock on July 8, 2026. These sales were not discretionary but were mandated \"sell to cover\" transactions to meet tax withholding obligations from the vesting of restricted stock units (RSUs). ", "url": "https://www.stocktitan.net/sec-filings/IMVT/form-4-immunovant-inc-insider-trading-activity-0a21246654a0.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:09:18", "published_display": "10 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant (IMVT) CTO offloads 3,487 shares in mandated RSU tax-withholding sales", "summary": "Immunovant's Chief Technology Officer, Jay S. Stout, sold 3,487 shares of IMVT common stock on July 8, 2026. These sales were non-discretionary \"sell to cover\" transactions to meet tax withholding obligations due to the vesting of restricted stock units (RSUs). The sales occurred", "url": "https://www.stocktitan.net/sec-filings/IMVT/form-4-immunovant-inc-insider-trading-activity-4dc2a4540837.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:09:18", "published_display": "10 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant (IMVT) legal chief sells 1,206 shares in tax \u201csell to cover\u201d", "summary": "Christopher Van Tuyl, Immunovant's Chief Legal Officer, sold 1,206 shares of common stock on July 8, 2026, in a mandatory \"sell to cover\" transaction. This sale, totaling approximately $47,702, was executed to satisfy tax withholding obligations following the vesting of previousl", "url": "https://www.stocktitan.net/sec-filings/IMVT/form-4-immunovant-inc-insider-trading-activity-a6b52dfbbd06.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:09:18", "published_display": "10 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $53", "summary": "LifeSci Capital has reiterated its Buy rating for Immunovant (IMVT.US) and increased its price target for the stock to $53. This indicates a continued positive outlook from the firm regarding Immunovant's financial prospects and market valuation.", "url": "https://www.moomoo.com/news/post/72720093/lifesci-capital-maintains-immunovant-imvtus-with-buy-rating-raises-target", "source_name": "Moomoo", "published_at": "2026-07-10T05:39:41", "published_display": "10 Jul 2026 05:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant Inc explores long term growth paths as autoimmune pipeline advances", "summary": "Immunovant Inc is focusing on developing therapies for autoimmune diseases and expanding its pipeline. The company's long-term growth is dependent on successful clinical trials", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/immunovant-inc-explores-long-term-growth-paths-as-autoimmune-pipeline/69731709", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-09T12:10:44", "published_display": "09 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant stock hits 52-week high at 39.28 USD", "summary": "Immunovant Inc. (IMVT) stock reached a new 52-week high of $39.28, marking a 130.79% increase over the past year. This surge is fueled by positive results from its Phase 2 rheumatoid arthritis study of IMVT-1402, with analysts from H.C. Wainwright, BofA Securities, and Stifel rai", "url": "https://www.investing.com/news/company-news/immunovant-stock-hits-52week-high-at-3928-usd-93CH-4779660", "source_name": "Investing.com", "published_at": "2026-07-08T04:40:23", "published_display": "08 Jul 2026 04:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding Momentum Shifts in (IMVT)", "summary": "This article analyzes Immunovant Inc. (IMVT) using AI-generated signals, indicating a strong overweight bias across all time horizons. It provides detailed trading strategies for different risk profiles, including position, momentum breakout, and risk hedging, along with multi-ti", "url": "https://news.stocktradersdaily.com/news_release/9/Understanding_Momentum_Shifts_in_IMVT_070826050202_1783501322.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-08T04:40:13", "published_display": "08 Jul 2026 04:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant stock hits 52-week high at 39.28 USD By Investing.com", "summary": "Immunovant Inc. (IMVT) stock reached a new 52-week high of $39.28, marking a 130.79% increase over the past year and achieving a market capitalization of $8.01 billion. This surge is supported by positive analyst ratings and promising results from its Phase 2 rheumatoid arthritis", "url": "https://za.investing.com/news/stock-market-news/immunovant-stock-hits-52week-high-at-3928-usd-93CH-4358888", "source_name": "Investing.com South Africa", "published_at": "2026-07-07T23:40:13", "published_display": "07 Jul 2026 23:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant Inc outlines its autoimmune drug pipeline as investors watch clinical milestones", "summary": "Immunovant Inc is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases using targeted antibody inhibition. The company's pipeline includes treatments for neuromuscular disorders and dermatologic autoimmune diseases, with development h", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/immunovant-inc-outlines-its-autoimmune-drug-pipeline-as-investors-watch/69714194", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T14:13:52", "published_display": "07 Jul 2026 14:13", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant (IMVT) CEO settles CVARs with small tax-related share sale", "summary": "Immunovant, Inc. CEO Eric Venker reported the settlement of 92,188 vested capped value appreciation rights (CVARs) into common stock on July 1, 2026, after meeting service, performance, and knock-in conditions. Concurrently, he disposed of 86,629 shares to the issuer and sold 3,0", "url": "https://www.stocktitan.net/sec-filings/IMVT/form-4-immunovant-inc-insider-trading-activity-975da4c0365c.html", "source_name": "Stock Titan", "published_at": "2026-07-07T04:40:23", "published_display": "07 Jul 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant CEO Eric Venker sells $118,980 of IMVT stock By Investing.com", "summary": "Immunovant CEO Eric Venker recently sold 3,092 shares of Immunovant (NASDAQ:IMVT) common stock for approximately $118,980. This \"sell to cover\" transaction was executed to fulfill tax withholding obligations tied to the vesting of Capped Value Appreciation Rights (CVARs). The sal", "url": "https://ca.investing.com/news/stock-market-news/immunovant-ceo-eric-venker-sells-118980-of-imvt-stock-93CH-4721754", "source_name": "Investing.com Canada", "published_at": "2026-07-07T04:09:56", "published_display": "07 Jul 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant CEO Eric Venker sells $118,980 of IMVT stock", "summary": "Immunovant CEO Eric Venker sold 3,092 shares of company common stock worth $118,980 to cover tax withholding obligations related to the vesting of Capped Value Appreciation Rights (CVARs). The transaction occurred on July 2, 2026, with the shares sold at $38.48 each. Following th", "url": "https://www.investing.com/news/insider-trading-news/immunovant-ceo-eric-venker-sells-118980-of-imvt-stock-93CH-4777626", "source_name": "Investing.com", "published_at": "2026-07-06T22:13:52", "published_display": "06 Jul 2026 22:13", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Immunovant Inc For: 6 July By Investing.com", "summary": "This article announces the filing of a Form 4 for Immunovant Inc. on July 6. Form 4 filings typically report changes in beneficial ownership of a company's securities by insiders. The article provides the title of the filing but no further details about its content.", "url": "https://ca.investing.com/news/stock-market-news/form-4-immunovantinc-for-6-july-93CH-4721762", "source_name": "Investing.com Canada", "published_at": "2026-07-06T21:09:55", "published_display": "06 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMVT - Immunovant Inc Revenue Breakdown", "summary": "This article provides a detailed financial overview of Immunovant Inc. (IMVT), covering key metrics such as market cap, income, sales, stock performance, and analyst recommendations. It highlights the company's valuation ratios, insider and institutional ownership, and profitabil", "url": "https://finviz.com/stock?t=IMVT&ty=rv", "source_name": "Finviz", "published_at": "2026-07-04T11:09:45", "published_display": "04 Jul 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chief Technology Officer Of Immunovant Sold 53% Of Their Shares", "summary": "Immunovant Inc.'s Chief Technology Officer, Jay Stout, recently sold US$1.5 million worth of stock, representing 53% of his holding. While insider selling at the current price isn't as concerning as selling at a lower price, there has been no insider buying in the last year. Insi", "url": "https://www.sahmcapital.com/news/content/chief-technology-officer-of-immunovant-sold-53-of-their-shares-2026-07-02", "source_name": "Sahm", "published_at": "2026-07-04T03:39:54", "published_display": "04 Jul 2026 03:39", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMVT - Immunovant Inc Options", "summary": "This page provides a detailed financial overview of Immunovant Inc (IMVT), including its latest stock performance, market capitalization, income, sales, and various financial ratios. It also lists key statistics such as EPS, insider and institutional ownership, profitability metr", "url": "https://finviz.com/stock?t=IMVT&ty=oc&ov=chain_strike&s=22", "source_name": "Finviz", "published_at": "2026-07-03T02:39:15", "published_display": "03 Jul 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citi Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $61", "summary": "Citi has reiterated its Buy rating for Immunovant (IMVT.US) and increased the target price to $61. This indicates a continued positive outlook from Citi on the company's stock performance.", "url": "https://www.moomoo.com/news/post/72258807/citi-maintains-immunovant-imvtus-with-buy-rating-raises-target-price", "source_name": "Moomoo", "published_at": "2026-06-30T14:39:15", "published_display": "30 Jun 2026 14:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant Insider Sold Shares Worth $1,532,309, According to a Recent SEC Filing", "summary": "An insider at Immunovant recently sold shares valued at $1,532,309, as disclosed in a recent SEC filing. This transaction could be of interest to investors tracking insider activity within the company. Further details would typically be available in the full SEC document.", "url": "https://www.moomoo.com/news/post/72169892/immunovant-insider-sold-shares-worth-1532309-according-to-a-recent?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-29T08:13:24", "published_display": "29 Jun 2026 08:13", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant CTO Jay Stout sells $1.53m in company stock", "summary": "Immunovant CTO Jay Stout sold 40,000 shares of the company\u2019s common stock for over $1.53 million on June 26, 2026. This sale occurred while Immunovant shares were trading near their 52-week high, with InvestingPro analysis suggesting the stock is overvalued. Despite this insider ", "url": "https://www.investing.com/news/insider-trading-news/immunovant-cto-jay-stout-sells-153m-in-company-stock-93CH-4763870", "source_name": "Investing.com", "published_at": "2026-06-27T13:40:21", "published_display": "27 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant (IMVT) CTO Jay S. Stout sells 40,000 shares in open-market trades", "summary": "Immunovant, Inc. CTO Jay S. Stout reported selling a total of 40,000 shares of the company's common stock in two open-market transactions on June 26, 2026. The shares were sold at weighted average prices of $38.18 and $38.94 per share, totaling approximately $1.53 million. Follow", "url": "https://www.stocktitan.net/sec-filings/IMVT/form-4-immunovant-inc-insider-trading-activity-6fe49a2c1b17.html", "source_name": "Stock Titan", "published_at": "2026-06-27T11:39:44", "published_display": "27 Jun 2026 11:39", "sentiment": "negative", "sentiment_pct": 14, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Melanie Gloria Sells 17,714 Shares of Immunovant I", "summary": "Melanie Gloria, Chief Operating Officer at a subsidiary of Immunovant Inc (IMVT), sold 17,714 shares of the company on June 26, 2026. Following this transaction, Gloria now owns 224,393 shares. Immunovant Inc is a clinical-stage biopharmaceutical company, and this sale marks part", "url": "https://www.gurufocus.com/news/8935069/insider-sell-melanie-gloria-sells-17714-shares-of-immunovant-inc-imvt", "source_name": "GuruFocus", "published_at": "2026-06-27T02:39:44", "published_display": "27 Jun 2026 02:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Immunovant, Inc. \u2013 NASDAQ:IMVT", "summary": "This article from TradingView focuses on the \"Price to book forward\" financial metric for Immunovant, Inc. (NASDAQ: IMVT). It is primarily a data page, displaying the period, value, and change for this specific financial indicator related to the biotechnology company. The content", "url": "https://www.tradingview.com/symbols/NASDAQ-IMVT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T01:13:24", "published_display": "27 Jun 2026 01:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant CFO Tiago Girao sells $384,600 in company stock", "summary": "Immunovant (NASDAQ:IMVT) CFO Tiago Girao sold 10,000 shares of company stock for approximately $384,600 after exercising stock options for the same number of shares. The sale occurred while Immunovant shares were trading near their 52-week high, having delivered a 137% return ove", "url": "https://www.investing.com/news/insider-trading-news/immunovant-cfo-tiago-girao-sells-384600-in-company-stock-93CH-4763861", "source_name": "Investing.com", "published_at": "2026-06-27T00:39:44", "published_display": "27 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant chief legal officer sells $682,886 in stock", "summary": "Christopher Van Tuyl, Chief Legal Officer at Immunovant, Inc. (NASDAQ:IMVT), sold 17,824 shares of company stock for $682,886 on June 26, 2026, after exercising stock options. The sales occurred while the stock was near its 52-week high, following a significant 137% gain over the", "url": "https://www.investing.com/news/insider-trading-news/immunovant-chief-legal-officer-sells-682886-in-stock-93CH-4763862", "source_name": "Investing.com", "published_at": "2026-06-27T00:39:44", "published_display": "27 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant (IMVT) Chief Legal Officer sells 17,824 shares after option exercise", "summary": "Immunovant, Inc.'s Chief Legal Officer, Christopher Van Tuyl, exercised options for 17,824 shares at $15.20 each and subsequently sold all these shares in open-market transactions for approximately $38.19 to $38.96 per share. Following these transactions, Van Tuyl directly holds ", "url": "https://www.stocktitan.net/sec-filings/IMVT/form-4-immunovant-inc-insider-trading-activity-14d28f1a79c5.html", "source_name": "Stock Titan", "published_at": "2026-06-27T00:10:21", "published_display": "27 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant (IMVT) COO sells 17,714 shares, keeps 224,393 stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPSE5lNFFXSF91b21JdmtiYVRoaGJUTEpPSGFpTmEteFcxbWZfbFAxMGhfRVpLakRrUi1MOEtzU3ZrV1RNby1ObWcwS182d1hIb1ZxMFB1clVkZXFzM1FMd0hOS3FaYy1qVmRZUUdlOUJrOHJoN2xfV3JqSTFNQ3JhVWY3MmJ2NXRMb1JCMlpQVGtINkY1WlhzN3ZQeUR5WHdlV3hWemxHcGk2TFIx?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Immunovant, Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQU0dEY3NEMzR1Tm8yWEtSWkcydG9QS2J1cllvRk5LTHMxa0cxdVl6RWkybGJUZlk5REZXb1NsbXlFaVVpWnNaMHFuVHVfX1ZzaGlRcDRqd2ktdExvMlhCdEdoUVJPYkdwa0FRS3FGNGFWSlVmSmxmVHpVNE1oZDRmRTlrN2stLXNNQVRyVFlPX19YNmo4dUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMVT (NASDAQ) Form 144 lists multiple vested restricted stock blocks, 40,000 header", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQb0lzbTc1YzJwem53SnpvME5zMC1BTmFBOGN2aFdSLWRDM3dsN0NKWXBtUWdmMHVJdjlFOTREVVFEcGJVSmRCSDhOTWN4TUJhMVdvM1pzR1RCMjBZOGNSYWQ4cmJKenhZOW5RZWtLd0xQcEV6V2xLNlFGZzNGQllMS0Y2OFVoU205ek5jQjV5MEV2ZkdYT0E?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant (IMVT) director sells 1,500 shares after option exercise", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOclR1R1ZUUkFFY3lVV29sN0ppOTRvZ0F4elRVQ3BRcTliWm1XdGEzMkpTaE5GUTBoM2FmVHM1V1dBVVZBaS1MZWV3Sl9PbjFiS3BZMkZEa3BKMXJFaDlUTnJwdHZoQmZzYVY2aE1EU3JLa1A1Z3F5ZnFxeHNpLWN6cTR2ZUtqVXltdF94UzFBNWxNcnpWSW9wZm9QSnJSV0I4cWt3QWQzSE15dkJ3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant (IMVT) Stock Could Be 14.1% Undervalued After Loss And Trial Updates", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-20T07:00:00+00:00", "published_display": "20 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/immunovant-imvt-3-6-since-153004858.html", "source_name": "Zacks", "published_at": "2026-06-19T15:30:04+00:00", "published_display": "19 Jun 2026 15:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant (IMVT) Is Up 7.5% After Batoclimab Shows Phase IIb CIDP Benefit - What's Changed", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant (IMVT) director trades 1,500 shares under 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNZ191X3NNU09xaTJ6czRnX1pGdVRxOGNxb3Y5eHA3bG1NM1pCWWQ4cEJtaDlKOHUwX1I3aTk3UzRTbG13NllPcVdOLUpJUTlJVXFSOHA4NTdiUTFvdGc2V2Mza05Vc1lnMHh0RzdmbzZOeU9fUnFvVmNXeHdTWjZpdU9TLUFuaG9jUjNSMG5QR2p1Rm5VaENsNy1DNll1WDNMNE9YV1R1ekNoYjVF?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant Stock Gains 12.4% in a Month: What's Driving It?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQVWJ6Mm9ZNTNZVjRiT0V3d2ZOS29RYVgwcElkQlg5ZDlXZ3FGQmplRVViVWxFekZOT3RGTUVjMHZVSnhFTDNGNTd1d19uLVNkdHJ6N0FoVjlaekxncWZTQmI0R0tFSlJTY0g0czVRSTJJTW9kSGdzVkdueGNvYjlWZWRMUmRZajhHNW9Ta1pSeHd2QTJpN293?oc=5", "source_name": "Market source", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Immunovant (IMVT) Valuation After Strong IMVT 1402 Phase 2 Rheumatoid Arthritis Trial Commentary", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/assessing-immunovant-imvt-valuation-strong-081221741.html", "source_name": "Simply Wall St.", "published_at": "2026-06-05T08:12:21+00:00", "published_display": "05 Jun 2026 08:12", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNbWFtRHZpVGZiSFc4OUN2amltaUNmNU5uMjVYVTEwYzhvbFB4T1N2M0VBaWFtREtQY1F0S0R3OXNqdWxCY21EQUpkOFprbjRwZzhxR0htR2o0YUFLUFlDd1BrdmYtVnNuZUVkWGVsSmFFVU1RUy1FTXVlbmhEQUctWjg3RktOd0ZKd0pWQW4ydTZsT0NJQ2E2MjRXLW0?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant(IMVT.US) Director Sells US$7.44 Million in Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPNkZRbmN3SzB2QlpsWGphNkZMYTFVZG85S093OVNUX0FMZTZYUGxIS25RLW1zS2ZUbDZnWDlMVHJENzBwbmlxZ3pnQkRZWlJ1NFA2TXN2c2hBaGczUE1vNnlYM0U3YjAyYmlxbDBzOE1zR1l4MFlaQnpYVjJfQW5xbkdBdUVrVVFGbVo4dFBzUktxNVpNc1BWdFdHcU40ODlvamc?oc=5", "source_name": "Moomoo", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist Lifts PT on Immunovant, Inc. (IMVT) But Maintains a Hold Rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPNFRlQkg1VUVJeEpfU2wyNDFncm9ia1FZNjQwN205SXZRUnp3SEZiTG5ZeU05WThRR29LZHNZV1QyNzlUY1VrRDBpeUNMcUdZdi1jSHZKZms5QmlqR0I1LVU5ZVkxaUE5RUJ5cGV4SFIzNHAwaGFrdzZlQ2JFZXhwVjhkR0FyWTljeFVOWUxtZlY2VS1FNGw3N21Rbw?oc=5", "source_name": "Market source", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan Raises Immunovant Price Target to $47 From $35, Overweight Rating Kept", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/jpmorgan-raises-immunovant-price-target-183230299.html", "source_name": "MT Newswires", "published_at": "2026-05-26T18:32:30+00:00", "published_display": "26 May 2026 18:32", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant (IMVT) Is Up 17.9% After Refocusing On IMVT-1402 Amid Wider Losses - Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOVERrUDdzZTV0c0dIWmZhejcwUmctcm5ZWW9PR2ozeUZOQWxkSWlVdHJEaG1EbXU2TzYzSmJNY01mRGdQbFFtUGVkdTluQTgtczJNaVBXSTB2NGhLVjZKSGxxcTlES3NaMWM0U3U4TVZhbmcxM2Nnb3hwcnBGVzZvZkl2UkcxS3NGYTBaWkZtVEFXZUZpeVR2eUJsMHVEZ2tUMlE?oc=5", "source_name": "Market source", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA raises Immunovant stock price target on higher peak sales outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOeERFa1RkWVRYUWZ4Rk1WNDRNRzBqMzNPcEJHcHNSYXQyVHVyc1NBdTgwdjE1d1FiVUNqOC12bkFnQXd6eXFHZFZuODhKWDdRNkFvcWFNaUU1N2RzWmJqQ0I2S1NhMElSVDYwUUt2UWNrUzRjd29xVEhkMktEZ3djck1IdkZwU18wNUd1SWpKMnYtMkZqbzR1S21VbzFIOUVxY0lYSTFoTkVVakRSbTVXNTVocnk3MHFfQ2pNeHllX3VMVy0wR3FCVDB3?oc=5", "source_name": "Investing.com", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nvidia, Astera Labs, Micron, Intel, United, Hasbro, Toll, Immunovant, Analog Devices, and More Movers", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE5pbFEyblFaaFItUmxyS1BUY2hpNDNrbnFWZ1phREwtUklnUXB2TjJndDhGNGUwSm5Oc1pwZ0RvdHNSblczUGdDZzUzRDQ5UzJiY0k5eXFVRWh5bFliNDBTYm1KTTA?oc=5", "source_name": "Barron's", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMMUNOVANT ($IMVT) Releases Q4 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxNRlU1dUFuMUtfU0QtbVJmMDQtclBCblJ1M2VodXk1ZkZVX0Z3SU5wRWF1Ry1RYWVUcFJNT0VqSVh6SkpBSmhqTmtiN2kyWFhFMDc1TVIwQmx0dTNBTDJ1WTI4cnFIaVhtR0h3REhIaXBVa1lZcGlGMlhPYkFVbFdGUlN3dEVSb184YXhr?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant Shares Rally on Positive Trial Results Despite Earnings Miss (IMVT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQOGNXaExyRjg4ZVlVQlMwVHhiQVNoOHExNkpBejVmQldteUJHcXFYQi1jNjBzMXFnNnpJY0JwTHpHT1UxV04ybGYxWUxuNFNhdE43Qi1NZUdLRFRfYW9JMGl5RjgwTVo0TzM0RmRrU1l3ZjJ6Uzltdm5zQ01BSjNUajRTdFpReWowX1h6LXRZc2x3b2ZLZEt1aHlYaHBSSFkyUFNaNW9WOGpSeE0?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant jumps 30.8% on upbeat IMVT-1402 rheumatoid arthritis update | IMVT Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOZWRMZEhLQVVfME1mYkNOQlVUSmJMank4Q3lLVnVWa1F0Mk5uZTFWQlo2ZmU0eTNLV3hyaWl2dzJOYkV5eE5fakVubzltbEd5SWVFWUdRamYyVjI1NjhPNmhsUXNNNTJicUtKeGdNV0pJd0wxYXpNTUVVN2V1OFFYdFBXM1dFeEZYdEFfRXFPcjRvOU9vZXlfeG1TVlVtVnFMejZEbzVTbG8?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant: Best-In-Class Ambitions, Still Unproven (NASDAQ:IMVT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQdU5iU2pCem5kM0RYcDlFblUwV1Z5Ql9QLUFmcU9tZkFQMjlMSkp2UVV5amJVQk1xeGFrVlFwNmZVa2pIWEhWTWtZekpFZnFqUXZKWDFvbXpvM1RGWm9Oc0dPSTlTUlI1N2I1aEMycTdZLW1HT0tEOWE3Z2NiaktxM0lucnBaRV9rUFVwQjhVTUF1dUJwMEFPck4zcVE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxQbjV2MjFzZmRGeE1VeU0wNzc4ZlUxMno5QUZlRnRScFQweVBTUDNudGRqMmhYbWFMbGozVXl5TXlBNExOQlNRbk5tb1djLXEwdEV1QTdFdjBxeW8yYVVZclhnX0hIdEhxdTNkZVZEZlNoVHo4VU5PNkl0aUpGZ1Z3alpFUTE?oc=5", "source_name": "Market source", "published_at": "2026-03-15T07:00:00+00:00", "published_display": "15 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxOdjNqcHZzQmJWajN4bXBnOW41U3FlSnY4bldzVFBzdEZSWFpwUEpQX0dJUlRCeG5oeXRlWVY0OTBPdmtsdVdxeExENGhTcDlpVEpLZG84XzA1M1lFaGsyZjhNY3Bxd3p3QUo0d1gzUjNIN1oxeEpLRUQyWFRFVUpiYzZVNE9wZDQ3X1A3S1RKN1hwOFpzREk4TklfYmhDXy16dFNYT2Z2TVZwS2RoQlZOcTI0V1F0OC1FeENqVGQzSEJVeDNZdXpYbXVyZGxyOWNHT2ZDZTNJVFg3WE56S1ZBcDF0WVQ?oc=5", "source_name": "The Motley Fool", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 98, "total_relevant": 61, "sentiment_summary": {"positive": 16, "negative": 8, "neutral": 37, "score": 53, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 21.6, "count": 38}, {"event": "earnings", "label": "Earnings", "weight": 7.5, "count": 15}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 16, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 39.71, "latest_week": "2026-07-10", "one_week_move": 2.4, "four_week_move": 18.1, "twelve_week_move": 35.5, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.32181, "market_dynamics_buy_signal": false, "relative_strength": 40.7235, "fair_value_gap": 50.6, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 44.5522, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+2.4% over one week, +18.1% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 63, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 11}, {"label": "Stock Titan", "count": 11}, {"label": "Investing.com", "count": 9}, {"label": "Moomoo", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "Investing.com Canada", "count": 2}, {"label": "Finviz", "count": 2}, {"label": "TradingView", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 53}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 38}, {"label": "Earnings", "count": 15}, {"label": "Analyst action", "count": 5}, {"label": "Deals and strategy", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "53", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+2.4% over one week, +18.1% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Form 4 Immunovant Inc For: 10 July By Investing.com"}], "updated_at": "2026-07-16T11:42:30.179105+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}